We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2010 by Far Eastern Memorial Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01176357
First Posted: August 6, 2010
Last Update Posted: August 6, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Far Eastern Memorial Hospital
  Purpose
Coronary artery disease (CAD), the most common type of heart disease, is caused by hardening of the arteries, or atherosclerosis that is an inflammatory process in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial trees. Epidemiological studies have found that increased cardiovascular risks are associated with increased levels of inflammatory cytokines (eg, interleukin-6 [IL-6] and tumor necrosis factor-alpha[TNF-alpha]) or their hepatic product, C-reactive protein (CRP). Higher expression of interleukin-Ibeta(IL-1beta),IL-6, monocyte chemotactic protein-1 (MCP-1), and TNF-alpha were observed in epicardial adipose tissues in patients with CAD. These findings suggested that the pericoronary tissues could be a source of inflammatory mediators or act as paracrine that lead to vascular inflammation on CAD pathogenesis. However, adiponectin, a kind of adipocytokine, produced and secreted exclusively by adipose tissue, has been reported to have a variety of anti-inflammatory functions against atherosclerosis, resulting in risk reduction for incidence of CAD events. It remains unclear whether adiponectin and inflammatory mediators in mediastinal adipose tissue contribute to CAD. We therefore aim to analyze the expression of adiponectin and inflammatory mediators in mediastinal adipose tissue between patients with CAD and with valve diseases, and to correlate these parameters with clinical atherosclerotic risks, medications (statins or antiplatelet), and blood sugar.

Condition
Coronary Artery Disease Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues Between Patients With Coronary Artery Diseases and With Valvular Diseases

Resource links provided by NLM:


Further study details as provided by Far Eastern Memorial Hospital:

Biospecimen Retention:   Samples Without DNA
Adipose tissue biopsy samples from mediastinal fat, epicardial fat, subcutaneous fat in thoracic region or abdominal region and subcutaneous fat in leg were obtained soon after sternotomy or thoracotomy before the initiation of cardiopulmonary bypass.

Estimated Enrollment: 60
Study Start Date: January 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
CABG
2
Valve surgery

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with CAD or with valve diseases proposed to have cardiac operations
Criteria

Inclusion Criteria:

  • patient underwent CABG or valve surgery in our hospital will be included

Exclusion Criteria:

  • liver disease
  • dhronic renal insufficiency
  • neoplastic diseases
  • taking steroids
  • congestive heart failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01176357


Contacts
Contact: Kuan-Ming Chiu, MD, PhD 886-2-89667000

Locations
Taiwan
FEMH Recruiting
Taipei, Taiwan
Contact: Kuan-Ming Chiu, MD, PhD    886-2-89667000      
Sponsors and Collaborators
Far Eastern Memorial Hospital
Investigators
Principal Investigator: Kuan-Ming Chiu, MD, PhD FEMH
  More Information

Responsible Party: Shih-Hong Huang, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01176357     History of Changes
Other Study ID Numbers: 96039
FEMH-96-D-003
First Submitted: February 6, 2009
First Posted: August 6, 2010
Last Update Posted: August 6, 2010
Last Verified: August 2010

Keywords provided by Far Eastern Memorial Hospital:
Coronary artery disease (CAD)
atherosclerosis
mediastinal adipose tissue
adiponectin, inflammatory mediators

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Atherosclerosis
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases